{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:46:18Z","timestamp":1760060778204,"version":"build-2065373602"},"reference-count":120,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:00:00Z","timestamp":1758326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sapienza University","award":["Ateneo RP124190F49E0F8C"],"award-info":[{"award-number":["Ateneo RP124190F49E0F8C"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Bladder cancer (BCa) is one of the most diagnosed cancers worldwide. It is classified as non-muscle-invasive (NMIB), confined to the mucosa, and muscle-invasive (MIB), extended to deeper layers or formed metastases. The poor outcomes associated with MIBC indicate the urgent need for candidate biomarkers to improve treatment strategies. Molecular characterisation of both NMIBC and MIBC, and especially the classification of tumours into molecular subtypes, could provide the development of novel therapeutics in high-risk muscle-invasive bladder cancer. A few studies have focused on pathways implicated in MIBC, including growth factors, DNA\u2013RNA modifying enzymes and the differential roles played by the NOTCH receptors. NOTCH1 has been revealed as a tumour suppressor; in contrast, NOTCH2 and NOTCH3 have demonstrated an oncogenic role in BCa. Recent reports have found that NOTCH2 and NOTCH3 are associated with poor prognosis. Moreover, inhibiting these NOTCH receptors effectively restrained BCa growth and metastasis, suggesting the potential value of targeting NOTCH as a promising therapeutic strategy for bladder cancer. Given the crucial role of the NOTCH pathway, we will discuss the different predictive value of the four NOTCH receptors and the potential of NOTCH-combined therapy in BCa.<\/jats:p>","DOI":"10.3390\/cancers17183078","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T10:05:17Z","timestamp":1758535517000},"page":"3078","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bladder Cancer: Uncovering the Predictive Role of NOTCH as an Emerging Candidate Biomarker for Therapeutic Strategies"],"prefix":"10.3390","volume":"17","author":[{"given":"Chiara","family":"Cusumano","sequence":"first","affiliation":[{"name":"Unit of Urology, Department of Surgical Sciences, Policlinico Tor Vergata University Hospital, University of Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6348-4566","authenticated-orcid":false,"given":"Federica","family":"Squillante","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Roma","sequence":"additional","affiliation":[{"name":"Unit of Urology, Department of Surgical Sciences, Policlinico Tor Vergata University Hospital, University of Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2445-1204","authenticated-orcid":false,"given":"Roberto","family":"Miano","sequence":"additional","affiliation":[{"name":"Unit of Urology, Department of Surgical Sciences, Policlinico Tor Vergata University Hospital, University of Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5765-2611","authenticated-orcid":false,"given":"Maria Pia","family":"Felli","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,20]]},"reference":[{"key":"ref_1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2011.1142","article-title":"Association Between Smoking and Risk of Bladder Cancer Among Men and Women","volume":"306","author":"Freedman","year":"2011","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/CEJ.0000000000000911","article-title":"Occupational Benzene Exposure and Risk of Kidney and Bladder Cancers: A Systematic Review and Meta-Analysis","volume":"34","author":"Seyyedsalehi","year":"2025","journal-title":"Eur. J. Cancer Prev."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Alouini, S. (2024). Risk Factors Associated with Urothelial Bladder Cancer. Int. J. Environ. Res. Public Health, 21.","DOI":"10.3390\/ijerph21070954"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.eururo.2020.11.041","article-title":"Bladder Cancer and Associated Risk Factors: The African Panorama","volume":"79","author":"Mantica","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Dobruch, J. (2021). Bladder Cancer: Current Challenges and Future Directions. Medicina, 57.","DOI":"10.3390\/medicina57080749"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1002\/cncr.29047","article-title":"Bladder Cancer Collaborative Stage Variables and Their Data Quality, Usage, and Clinical Implications: A Review of SEER Data, 2004\u20132010","volume":"120","author":"Charlton","year":"2014","journal-title":"Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3233\/BLC-230043","article-title":"New Intravesical Agents for BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer Bladder","volume":"9","author":"Asimakopoulos","year":"2023","journal-title":"Bladder Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.euo.2020.12.002","article-title":"Prognostic Value of the WHO1973 and WHO2004\/2016 Classification Systems for Grade in Primary Ta\/T1 Non-Muscle-Invasive Bladder Cancer: A Multicenter European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel Study","volume":"4","author":"Hentschel","year":"2021","journal-title":"Eur. Urol. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting Recurrence and Progression in Individual Patients with Stage TaT1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.urology.2008.12.047","article-title":"Recurrence at Three Months and High-Grade Recurrence as Prognostic Factor of Progression in Multivariate Analysis of T1G2 Bladder Tumors","volume":"73","author":"Palou","year":"2009","journal-title":"Urology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated with Bacillus Calmette-Guerin: The CUETO Scoring Model","volume":"182","author":"Madero","year":"2009","journal-title":"J. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-Specific and Overall Survival in Non-Muscle-Invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1\u20133 Years of Maintenance Bacillus Calmette-Guerin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"7892","DOI":"10.1245\/s10434-023-14051-9","article-title":"Cancer-Specific Survival of Patients with Non-Muscle-Invasive Bladder Cancer: A Population-Based Analysis","volume":"30","author":"Borkowski","year":"2023","journal-title":"Ann. Surg. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Asimakopoulos, A.D., Colalillo, G., Telesca, R., Mauriello, A., Miano, R., Di Stasi, S.M., Germani, S., Finazzi Agr\u00f2, E., Petrozza, V., and Caruso, G. (2021). T1 Bladder Cancer: Comparison of the Prognostic Impact of Two Substaging Systems on Disease Recurrence and Progression and Suggestion of a Novel Nomogram. Front. Surg., 8.","DOI":"10.3389\/fsurg.2021.704902"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-Muscle-Invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004\/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"E306","DOI":"10.5489\/cuaj.1514","article-title":"Tumour Stage on Re-Staging Transurethral Resection Predicts Recurrence and Progression-Free Survival of Patients with High-Risk Non-Muscle Invasive Bladder Cancer","volume":"8","author":"Bishr","year":"2014","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2011.10.029","article-title":"Female Gender and Carcinoma in Situ in the Prostatic Urethra Are Prognostic Factors for Recurrence, Progression, and Disease-Specific Mortality in T1G3 Bladder Cancer Patients Treated with Bacillus Calmette-Guerin","volume":"62","author":"Palou","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ijsu.2018.02.049","article-title":"Comparison of the Prognosis of Primary and Progressive Muscle-Invasive Bladder Cancer after Radical Cystectomy: A Systematic Review and Meta-Analysis","volume":"52","author":"Chen","year":"2018","journal-title":"Int. J. Surg."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Ge, P., Wang, L., Lu, M., Mao, L., Li, W., Wen, R., Lin, J., Wang, J., and Chen, J. (2018). Oncological Outcome of Primary and Secondary Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-26002-6"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bju.16366","article-title":"Trimodal Therapy vs Radical Cystectomy in Patients with Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Comparative Studies","volume":"134","author":"Ditonno","year":"2024","journal-title":"BJU Int."},{"key":"ref_22","first-page":"100264","article-title":"Survival after Radical Cystectomy: Progressive versus De Novo Muscle Invasive Bladder Cancer","volume":"25","author":"Vlaming","year":"2020","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.urolonc.2017.10.002","article-title":"A Systematic Review and Meta-Analysis on the Oncological Long-Term Outcomes after Trimodality Therapy and Radical Cystectomy with or without Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer","volume":"36","author":"Fahmy","year":"2018","journal-title":"Urol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2281654","DOI":"10.1080\/07853890.2023.2281654","article-title":"Three versus Four Cycles of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis","volume":"55","author":"Wang","year":"2023","journal-title":"Ann. Med."},{"key":"ref_25","unstructured":"Advanced Bladder Cancer Meta-analysis Collaboration (2004). Neo-adjuvant Chemotherapy for Invasive Bladder Cancer. Cochrane Database Syst. Rev., 2004, CD005246."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s00345-020-03436-0","article-title":"Incidence and Outcome of Salvage Cystectomy after Bladder Sparing Therapy for Muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis","volume":"39","author":"Schuettfort","year":"2021","journal-title":"World J. Urol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.eururo.2012.05.008","article-title":"Follow-up After Surgical Treatment of Bladder Cancer: A Critical Analysis of the Literature","volume":"62","author":"Soukup","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00345-006-0117-8","article-title":"Staged Based Directed Surveillance of Invasive Bladder Cancer Following Radical Cystectomy: Valuable and Effective?","volume":"24","author":"Donat","year":"2006","journal-title":"World J. Urol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/MOU.0b013e32833cf10e","article-title":"Follow-up of Patients after Curative Bladder Cancer Treatment: Guidelines vs. Practice","volume":"20","author":"Vrooman","year":"2010","journal-title":"Curr. Opin. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S247","DOI":"10.33549\/physiolres.935187","article-title":"Molecular Biomarkers of Bladder Cancer: A Mini-Review","volume":"72","author":"Novakova","year":"2023","journal-title":"Physiol. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/s41467-021-22465-w","article-title":"An Integrated Multi-Omics Analysis Identifies Prognostic Molecular Subtypes of Non-Muscle-Invasive Bladder Cancer","volume":"12","author":"Lindskrog","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","article-title":"Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma","volume":"30","author":"Hedegaard","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"100472","DOI":"10.1016\/j.xcrm.2021.100472","article-title":"Stage-Stratified Molecular Profiling of Non-Muscle-Invasive Bladder Cancer Enhances Biological, Clinical, and Therapeutic Insight","volume":"2","author":"Hurst","year":"2021","journal-title":"Cell Rep. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","article-title":"Bladder Cancer","volume":"9","author":"Hansel","year":"2023","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1073\/pnas.88.4.1095","article-title":"Isolation of an Additional Member of the Fibroblast Growth Factor Receptor Family, FGFR-3","volume":"88","author":"Keegan","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Harsanyi, S., Novakova, Z.V., Bevizova, K., Danisovic, L., and Ziaran, S. (2022). Biomarkers of Bladder Cancer: Cell-Free DNA, Epigenetic Modifications and Non-Coding RNAs. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232113206"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10555-015-9579-8","article-title":"Fibroblast Growth Factor Receptor Signaling in Hereditary and Neoplastic Disease: Biologic and Clinical Implications","volume":"34","author":"Helsten","year":"2015","journal-title":"Cancer Metastasis Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"102530","DOI":"10.1016\/j.ctrv.2023.102530","article-title":"Role of FGFR3 in Bladder Cancer: Treatment Landscape and Future Challenges","volume":"115","author":"Ascione","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"AACR Project GENIE Consortium (2017). AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov., 7, 818\u2013831.","DOI":"10.1158\/2159-8290.CD-17-0151"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1136\/jclinpath-2020-207115","article-title":"Fibroblast Growth Factor Receptor (FGFR) Gene: Pathogenesis and Treatment Implications in Urothelial Carcinoma of the Bladder","volume":"74","author":"Cheng","year":"2021","journal-title":"J. Clin. Pathol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/cac2.12602","article-title":"FGFR3 Alterations in Bladder Cancer: Sensitivity and Resistance to Targeted Therapies","volume":"44","author":"Noeraparast","year":"2024","journal-title":"Cancer Commun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.eururo.2020.07.002","article-title":"FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?","volume":"78","author":"Mertens","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1111\/jcmm.14114","article-title":"Inhibition of Stearoyl CoA Desaturase-1 Activity Suppresses Tumour Progression and Improves Prognosis in Human Bladder Cancer","volume":"23","author":"Piao","year":"2019","journal-title":"J. Cell Mol. Med."},{"key":"ref_44","first-page":"2787","article-title":"Oncogenic Activation of Fibroblast Growth Factor Receptor-3 and RAS Genes as Non-Overlapping Mutual Exclusive Events in Urinary Bladder Cancer","volume":"17","author":"Pandith","year":"2016","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1038\/sj.onc.1208705","article-title":"FGFR3 and Ras Gene Mutations Are Mutually Exclusive Genetic Events in Urothelial Cell Carcinoma","volume":"24","author":"Jebar","year":"2005","journal-title":"Oncogene"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.humpath.2011.10.026","article-title":"Mutations in FGFR3 and PIK3CA, Singly or Combined with RAS and AKT1, Are Associated with AKT but Not with MAPK Pathway Activation in Urothelial Bladder Cancer","volume":"43","author":"Juanpere","year":"2012","journal-title":"Hum. Pathol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41576-022-00459-8","article-title":"Functions and Consequences of AID\/APOBEC-Mediated DNA and RNA Deamination","volume":"23","author":"Pecori","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s43046-024-00250-2","article-title":"Clinicopathological Significance of C-MET and HER2 Altered Expression in Bladder Cancer","volume":"36","author":"Naguib","year":"2024","journal-title":"J. Egypt. Natl. Canc. Inst."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.euros.2022.02.004","article-title":"STAG2 Protein Expression in Non\u2013Muscle-Invasive Bladder Cancer: Associations with Sex, Genomic and Transcriptomic Changes, and Clinical Outcomes","volume":"38","author":"Gordon","year":"2022","journal-title":"Eur. Urol. Open Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1038\/onc.2016.133","article-title":"Characterization of Activating Mutations of NOTCH3 in T-Cell Acute Lymphoblastic Leukemia and Anti-Leukemic Activity of NOTCH3 Inhibitory Antibodies","volume":"35","author":"Hu","year":"2016","journal-title":"Oncogene"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Australian Pancreatic Cancer Genome Initiative, ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, ICGC PedBrain, Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Aparicio, S.A.J.R., Behjati, S., and Biankin, A.V. (2013). Signatures of Mutational Processes in Human Cancer. Nature, 500, 415\u2013421.","DOI":"10.1038\/nature12477"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41585-020-0304-1","article-title":"Genomic Heterogeneity in Bladder Cancer: Challenges and Possible Solutions to Improve Outcomes","volume":"17","author":"Meeks","year":"2020","journal-title":"Nat. Rev. Urol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.cell.2018.07.036","article-title":"Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer","volume":"174","author":"Robertson","year":"2018","journal-title":"Cell"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.humpath.2008.09.011","article-title":"Phosphorylated Hepatocyte Growth Factor Receptor\/c-Met Is Associated with Tumor Growth and Prognosis in Patients with Bladder Cancer: Correlation with Matrix Metalloproteinase-2 and -7 and E-Cadherin","volume":"40","author":"Miyata","year":"2009","journal-title":"Hum. Pathol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Zhdanovskaya, N., Firrincieli, M., Lazzari, S., Pace, E., Scribani Rossi, P., Felli, M.P., Talora, C., Screpanti, I., and Palermo, R. (2021). Targeting Notch to Maximize Chemotherapeutic Benefits: Rationale, Advanced Strategies, and Future Perspectives. Cancers, 13.","DOI":"10.3390\/cancers13205106"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1158\/1078-0432.CCR-18-1001","article-title":"ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer","volume":"25","author":"Li","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1517\/14728222.2014.914173","article-title":"Transcription Factor Sp1, Also Known as Specificity Protein 1 as a Therapeutic Target","volume":"18","author":"Safe","year":"2014","journal-title":"Expert. Opin. Ther. Targets"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1158\/1055-9965.EPI-07-2791","article-title":"Sp1, a New Biomarker That Identifies a Subset of Aggressive Pancreatic Ductal Adenocarcinoma","volume":"17","author":"Jiang","year":"2008","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.suronc.2015.05.004","article-title":"High Co-Expression of Sp1 and HER-2 Is Correlated with Poor Prognosis of Gastric Cancer Patients","volume":"24","author":"Jiang","year":"2015","journal-title":"Surg. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s11255-022-03212-6","article-title":"Sp1 Is Overexpressed and Associated with Progression and Poor Prognosis in Bladder Urothelial Carcinoma Patients","volume":"54","author":"Zhu","year":"2022","journal-title":"Int. Urol. Nephrol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","article-title":"Next-Generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets","volume":"72","author":"Pietzak","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Research Network (2014). Comprehensive Molecular Characterization of Urothelial Bladder Carcinoma. Nature, 507, 315\u2013322.","DOI":"10.1038\/nature12965"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41585-018-0005-1","article-title":"Unravelling Disparate Roles of NOTCH in Bladder Cancer","volume":"15","author":"Goriki","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/978-3-030-36422-9_10","article-title":"Molecular Mechanisms of Notch Signaling in Lymphoid Cell Lineages Development: NF-\u03baB and Beyond","volume":"1227","author":"Tsaouli","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrc3035","article-title":"Notch Signalling in Solid Tumours: A Little Bit of Everything but Not All the Time","volume":"11","author":"Ranganathan","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.bbadis.2008.06.008","article-title":"Notch Signaling and Diseases: An Evolutionary Journey from a Simple Beginning to Complex Outcomes","volume":"1782","author":"Talora","year":"2008","journal-title":"Biochim. Et. Biophys. Acta (BBA) Mol. Basis Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.1102160","article-title":"Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia","volume":"306","author":"Weng","year":"2004","journal-title":"Science"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/0092-8674(91)90111-B","article-title":"TAN-l, the Human Homolog of the Drosophila Notch Gene, Is Broken by Chromosomal Translocations in T Lymphoblastic Neoplasms","volume":"66","author":"Ellisen","year":"1991","journal-title":"Cell"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1038\/s41388-024-03079-0","article-title":"Notch3-Regulated microRNAs Impair CXCR4-Dependent Maturation of Thymocytes Allowing Maintenance and Progression of T-ALL","volume":"43","author":"Sergio","year":"2024","journal-title":"Oncogene"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1073\/pnas.0802047105","article-title":"Notch Signaling Mediates Hypoxia-Induced Tumor Cell Migration and Invasion","volume":"105","author":"Sahlgren","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.cell.2010.04.020","article-title":"A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth","volume":"141","author":"Roesch","year":"2010","journal-title":"Cell"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ccr.2013.05.021","article-title":"A Rare Population of CD24+ITGB4+Notchhi Cells Drives Tumor Propagation in NSCLC and Requires Notch3 for Self-Renewal","volume":"24","author":"Zheng","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive Genomic Profiles of Small Cell Lung Cancer","volume":"524","author":"George","year":"2015","journal-title":"Nature"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1084\/jem.20121484","article-title":"Notch Pathway Activation Targets AML-Initiating Cell Homeostasis and Differentiation","volume":"210","author":"Lobry","year":"2013","journal-title":"J. Exp. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/nature03659","article-title":"Notch\/\u03b3-Secretase Inhibition Turns Proliferative Cells in Intestinal Crypts and Adenomas into Goblet Cells","volume":"435","author":"Riccio","year":"2005","journal-title":"Nature"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/nature08878","article-title":"Therapeutic Antibody Targeting of Individual Notch Receptors","volume":"464","author":"Wu","year":"2010","journal-title":"Nature"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"13438","DOI":"10.1073\/pnas.1002423107","article-title":"Notch2 Is Required for Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Ductal Adenocarcinoma","volume":"107","author":"Mazur","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1158\/1078-0432.CCR-15-2360","article-title":"Not All NOTCH Is Created Equal: The Oncogenic Role of NOTCH2 in Bladder Cancer and Its Implications for Targeted Therapy","volume":"22","author":"Hayashi","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_79","first-page":"2430","article-title":"High Expression of Notch Ligand Jagged2 Is Associated with the Metastasis and Recurrence in Urothelial Carcinoma of Bladder","volume":"6","author":"Li","year":"2013","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/nm.3678","article-title":"A New Tumor Suppressor Role for the Notch Pathway in Bladder Cancer","volume":"20","author":"Rampias","year":"2014","journal-title":"Nat. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.juro.2008.02.037","article-title":"Association of Low Expression of Notch-1 and Jagged-1 in Human Papillary Bladder Cancer and Shorter Survival","volume":"180","author":"Shi","year":"2008","journal-title":"J. Urol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Greife, A., Jankowiak, S., Steinbring, J., Nikpour, P., Niegisch, G., Hoffmann, M.J., and Schulz, W.A. (2014). Canonical Notch Signalling Is Inactive in Urothelial Carcinoma. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-628"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1172\/JCI78185","article-title":"NOTCH Pathway Inactivation Promotes Bladder Cancer Progression","volume":"125","author":"Maraver","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.18632\/oncotarget.3183","article-title":"Bladder Cancer and the Notch Pathway","volume":"6","author":"Serrano","year":"2015","journal-title":"Oncotarget"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/sj.embor.7400421","article-title":"Tumour-suppression Activity of the Proapoptotic Regulator Par4","volume":"6","author":"Duran","year":"2005","journal-title":"EMBO Rep."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1111\/cas.14878","article-title":"Therapeutic and Prognostic Implications of NOTCH and MAPK Signaling in Bladder Cancer","volume":"112","author":"Schulz","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"216807","DOI":"10.1016\/j.canlet.2024.216807","article-title":"LRP1 Induces Anti-PD-1 Resistance by Modulating the DLL4-NOTCH2-CCL2 Axis and Redirecting M2-like Macrophage Polarisation in Bladder Cancer","volume":"593","author":"Lin","year":"2024","journal-title":"Cancer Lett."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s41065-025-00384-w","article-title":"BIN1 Inhibited Tumor Growth, Metastasis and Stemness by ALDH1\/NOTCH Pathway in Bladder Carcinoma","volume":"162","author":"Chen","year":"2025","journal-title":"Hereditas"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ijrobp.2024.12.019","article-title":"Combined Molecular Subclass and Immune Phenotype Correlate to Atezolizumab Plus Radiation Therapy Response in Invasive Bladder Cancer: BPT-ART Phase 2 Study","volume":"122","author":"Nagumo","year":"2025","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Zhang, C., Weimann, A., Stolzenburg, J.-U., Neuhaus, J., and Berndt-Paetz, M. (2025). Notch2\/3-DLL4 Interaction in Urothelial Cancer Cell Lines Supports a Tumorigenic Role of Notch Signaling Pathways in Bladder Carcinoma. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0317709"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2018.09.002","article-title":"Genomic Differences Between \u201cPrimary\u201d and \u201cSecondary\u201d Muscle-Invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-Based Neoadjuvant Chemotherapy","volume":"75","author":"Pietzak","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e2400287","DOI":"10.1200\/PO.24.00287","article-title":"DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial","volume":"8","author":"Iyer","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"34362","DOI":"10.18632\/oncotarget.16156","article-title":"Notch3 Overexpression Enhances Progression and Chemoresistance of Urothelial Carcinoma","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Tottone, L., Zhdanovskaya, N., Carmona Pesta\u00f1a, \u00c1., Zampieri, M., Simeoni, F., Lazzari, S., Ruocco, V., Pelullo, M., Caiafa, P., and Felli, M.P. (2019). Histone Modifications Drive Aberrant Notch3 Expression\/Activity and Growth in T-ALL. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00198"},{"key":"ref_95","first-page":"523","article-title":"The Association between NOTCH3 Expression and the Clinical Outcome in the Urothelial Bladder Cancer Patients","volume":"24","author":"Stojnev","year":"2022","journal-title":"Bosn. J. Basic. Med. Sci."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"274","DOI":"10.5114\/ceji.2023.134748","article-title":"Notch Signaling Pathway-Based Classification of Bladder Cancer in Relation to Tumor Immune Infiltration","volume":"48","author":"Bin","year":"2023","journal-title":"Cent. Eur. J. Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41419-024-07241-0","article-title":"NOTCH3 Promotes Malignant Progression of Bladder Cancer by Directly Regulating SPP1 and Activating PI3K\/AKT Pathway","volume":"15","author":"Liu","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Nedjadi, T., Ahmed, M.E., Ansari, H.R., Aouabdi, S., and Al-Maghrabi, J. (2023). Identification of SPP1 as a Prognostic Biomarker and Immune Cells Modulator in Urothelial Bladder Cancer: A Bioinformatics Analysis. Cancers, 15.","DOI":"10.3390\/cancers15235704"},{"key":"ref_99","first-page":"102892","article-title":"Comprehensive Genomic Profiling of Primary Bladder Mucinous Adenocarcinoma, a Rare Genitourinary Cancer: A Case Report","volume":"58","author":"Yamamoto","year":"2025","journal-title":"Urol. Case Rep."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Hu, J., Ye, F., Cui, M., Lee, P., Wei, C., Hao, Y., Wang, X., Wang, Y., Lu, Z., and Galsky, M. (2016). Protein Profiling of Bladder Urothelial Cell Carcinoma. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0161922"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Long, J., Wang, D., Yang, X., Wang, A., Lin, Y., Zheng, M., Zhang, H., Sang, X., Wang, H., and Hu, K. (2021). Identification of NOTCH4 Mutation as a Response Biomarker for Immune Checkpoint Inhibitor Therapy. BMC Med., 19.","DOI":"10.1186\/s12916-021-02031-3"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"115672","DOI":"10.1016\/j.envres.2023.115672","article-title":"New Insight in Urological Cancer Therapy: From Epithelial-Mesenchymal Transition (EMT) to Application of Nano-Biomaterials","volume":"229","author":"He","year":"2023","journal-title":"Environ. Res."},{"key":"ref_103","first-page":"1709","article-title":"Serial Assessment of Circulating T Lymphocyte Phenotype and Receptor Repertoire During Treatment of Non-Muscle Invasive Bladder Cancer with Adoptive T Cell Immunotherapy","volume":"11","author":"Wang","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.3892\/mmr.2015.3750","article-title":"\u03b3-Secretase Inhibitor Inhibits Bladder Cancer Cell Drug Resistance and Invasion by Reducing Epithelial-Mesenchymal Transition","volume":"12","author":"Wang","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"ref_105","first-page":"36.e19","article-title":"Inhibition of Presenilins Attenuates Proliferation and Invasion in Bladder Cancer Cells through Multiple Pathways","volume":"32","author":"Gai","year":"2014","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1791222","DOI":"10.1155\/2021\/1791222","article-title":"Notch1 Signaling Contributes to Mechanical Allodynia Associated with Cyclophosphamide-Induced Cystitis by Promoting Microglia Activation and Neuroinflammation","volume":"2021","author":"Chen","year":"2021","journal-title":"Mediat. Inflamm."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.canlet.2015.07.048","article-title":"Notch Signaling: An Emerging Therapeutic Target for Cancer Treatment","volume":"369","author":"Yuan","year":"2015","journal-title":"Cancer Lett."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/cbdd.13132","article-title":"Perspectives on the Discovery of NOTCH2-Specific Inhibitors","volume":"91","author":"Dobranowski","year":"2018","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s10637-018-0714-6","article-title":"A Phase 1 Dose Escalation and Expansion Study of Tarextumab (OMP-59R5) in Patients with Solid Tumors","volume":"37","author":"Smith","year":"2019","journal-title":"Invest. New Drugs"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s10637-019-00754-y","article-title":"A Phase I, Dose-Escalation Study of PF-06650808, an Anti-Notch3 Antibody\u2013Drug Conjugate, in Patients with Breast Cancer and Other Advanced Solid Tumors","volume":"38","author":"Rosen","year":"2020","journal-title":"Invest. New Drugs"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Sergio, I., Varricchio, C., Squillante, F., Cantale Aeo, N.M., Campese, A.F., and Felli, M.P. (2024). Notch Inhibitors and BH3 Mimetics in T-Cell Acute Lymphoblastic Leukemia. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252312839"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e472822","DOI":"10.1200\/EDBK-25-472822","article-title":"Advancing Perioperative Treatment Options for Localized Muscle-Invasive Bladder Cancer: A Step Forward","volume":"45","author":"Ribal","year":"2025","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13045-020-01015-9","article-title":"Targeting Oncogenic Notch Signaling with SERCA Inhibitors","volume":"14","author":"Pagliaro","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41419-021-03836-z","article-title":"Fosciclopirox Suppresses Growth of High-Grade Urothelial Cancer by Targeting the \u03b3-Secretase Complex","volume":"12","author":"Weir","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41389-024-00529-y","article-title":"Combined Inhibition of PI3K and STAT3 Signaling Effectively Inhibits Bladder Cancer Growth","volume":"13","author":"Peng","year":"2024","journal-title":"Oncogenesis"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3390\/curroncol32040236","article-title":"Crizotinib Inhibits Viability, Migration, and Invasion by Suppressing the c-Met\/PI3K\/Akt Pathway in the Three-Dimensional Bladder Cancer Spheroid Model","volume":"32","author":"Song","year":"2025","journal-title":"Curr. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-20-4175","article-title":"Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin","volume":"27","author":"Chu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2302377","DOI":"10.1002\/advs.202302377","article-title":"A HER2-targeted Antibody-Drug Conjugate, RC48-ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Instillation in Preclinical Models of Bladder Cancer","volume":"10","author":"Hong","year":"2023","journal-title":"Adv. Sci."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Hao, N., Yang, D., Liu, T., Liu, S., Lu, X., and Chen, L. (2022). Laminin-Integrin A6b4 Interaction Activates Notch Signaling to Facilitate Bladder Cancer Development. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09645-7"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/18\/3078\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:46:24Z","timestamp":1760035584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/18\/3078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,20]]},"references-count":120,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["cancers17183078"],"URL":"https:\/\/doi.org\/10.3390\/cancers17183078","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2025,9,20]]}}}